Literature DB >> 26699492

APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.

Opeyemi A Olabisi1, Jia-Yue Zhang2, Lynn VerPlank3, Nathan Zahler3, Salvatore DiBartolo4, John F Heneghan5, Johannes S Schlöndorff2, Jung Hee Suh2, Paul Yan2, Seth L Alper5, David J Friedman5, Martin R Pollak6.   

Abstract

Two specific genetic variants of the apolipoprotein L1 (APOL1) gene are responsible for the high rate of kidney disease in people of recent African ancestry. Expression in cultured cells of these APOL1 risk variants, commonly referred to as G1 and G2, results in significant cytotoxicity. The underlying mechanism of this cytotoxicity is poorly understood. We hypothesized that this cytotoxicity is mediated by APOL1 risk variant-induced dysregulation of intracellular signaling relevant for cell survival. To test this hypothesis, we conditionally expressed WT human APOL1 (G0), the APOL1 G1 variant, or the APOL1 G2 variant in human embryonic kidney cells (T-REx-293) using a tetracycline-mediated (Tet-On) system. We found that expression of either G1 or G2 APOL1 variants increased apparent cell swelling and cell death compared with G0-expressing cells. These manifestations of cytotoxicity were preceded by G1 or G2 APOL1-induced net efflux of intracellular potassium as measured by X-ray fluorescence, resulting in the activation of stress-activated protein kinases (SAPKs), p38 MAPK, and JNK. Prevention of net K(+) efflux inhibited activation of these SAPKs by APOL1 G1 or G2. Furthermore, inhibition of SAPK signaling and inhibition of net K(+) efflux abrogated cytotoxicity associated with expression of APOL1 risk variants. These findings in cell culture raise the possibility that nephrotoxicity of APOL1 risk variants may be mediated by APOL1 risk variant-induced net loss of intracellular K(+) and subsequent induction of stress-activated protein kinase pathways.

Entities:  

Keywords:  African-American; apolipoprotein L1; genetics; kidney; protein kinase

Mesh:

Substances:

Year:  2015        PMID: 26699492      PMCID: PMC4743809          DOI: 10.1073/pnas.1522913113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

1.  The innate immune factor apolipoprotein L1 restricts HIV-1 infection.

Authors:  Harry E Taylor; Atanu K Khatua; Waldemar Popik
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

2.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

3.  Rapid identification of metal-binding peptoid oligomers by on-resin X-ray fluorescence screening.

Authors:  Danielle M Nalband; Benjamin P Warner; Nathan H Zahler; Kent Kirshenbaum
Journal:  Biopolymers       Date:  2014-09       Impact factor: 2.505

Review 4.  Familial FSGS.

Authors:  Martin R Pollak
Journal:  Adv Chronic Kidney Dis       Date:  2014-09       Impact factor: 3.620

5.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.

Authors:  Alex N Kasembeli; Raquel Duarte; Michèle Ramsay; Pulane Mosiane; Caroline Dickens; Thérèse Dix-Peek; Sophie Limou; Efe Sezgin; George W Nelson; Agnes B Fogo; Stewart Goetsch; Jeffrey B Kopp; Cheryl A Winkler; Saraladevi Naicker
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

6.  Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy.

Authors:  Leyi Gu; Yan Dai; Jin Xu; Sandeep Mallipattu; Lewis Kaufman; Paul E Klotman; John C He; Peter Y Chuang
Journal:  AIDS       Date:  2013-04-24       Impact factor: 4.177

7.  High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria.

Authors:  Ifeoma I Ulasi; Shay Tzur; Walter G Wasser; Revital Shemer; Etty Kruzel; Elena Feigin; Chinwuba K Ijoma; Obinna D Onodugo; Julius U Okoye; Ejikeme B Arodiwe; Ngozi A Ifebunandu; Chinwe J Chukwuka; Cajetan C Onyedum; Uchenna N Ijoma; Emmanuel Nna; Macaulay Onuigbo; Saharon Rosset; Karl Skorecki
Journal:  Nephron Clin Pract       Date:  2013-07-13

8.  APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.

Authors:  Xiqian Lan; Aakash Jhaveri; Kang Cheng; Hongxiu Wen; Moin A Saleem; Peter W Mathieson; Joanna Mikulak; Sharon Aviram; Ashwani Malhotra; Karl Skorecki; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-04

9.  Gp130-dependent signaling in the podocyte.

Authors:  Yoshikuni Nagayama; Gerald S Braun; Christina M Jakobs; Yuichi Maruta; Claudia R van Roeyen; Barbara M Klinkhammer; Peter Boor; Luigi Villa; Ute Raffetseder; Christian Trautwein; Dieter Görtz; Gerhard Müller-Newen; Tammo Ostendorf; Jürgen Floege
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-04

10.  Caspase-1-dependent and -independent cell death pathways in Burkholderia pseudomallei infection of macrophages.

Authors:  Antje Bast; Kathrin Krause; Imke H E Schmidt; Matsayapan Pudla; Stefanie Brakopp; Verena Hopf; Katrin Breitbach; Ivo Steinmetz
Journal:  PLoS Pathog       Date:  2014-03-13       Impact factor: 6.823

View more
  92 in total

1.  Chronic kidney disease: Potassium efflux in APOL1 nephropathy.

Authors:  Jessica K Edwards
Journal:  Nat Rev Nephrol       Date:  2016-01-19       Impact factor: 28.314

Review 2.  ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus.

Authors:  Ashira D Blazer; Robert M Clancy
Journal:  Curr Rheumatol Rep       Date:  2017-03       Impact factor: 4.592

3.  Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Authors:  Herbert Lannon; Shrijal S Shah; Leny Dias; Daniel Blackler; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  Kidney Int       Date:  2019-08-01       Impact factor: 10.612

Review 4.  Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.

Authors:  Kirk N Campbell; James A Tumlin
Journal:  Am J Nephrol       Date:  2018-05-31       Impact factor: 3.754

Review 5.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

6.  APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore.

Authors:  Shrijal S Shah; Herbert Lannon; Leny Dias; Jia-Yue Zhang; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  J Am Soc Nephrol       Date:  2019-09-26       Impact factor: 10.121

Review 7.  Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.

Authors:  Kimberly J Reidy; Rebecca Hjorten; Rulan S Parekh
Journal:  Curr Opin Pediatr       Date:  2018-04       Impact factor: 2.856

8.  ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.

Authors:  John F O'Toole; William Schilling; Diana Kunze; Sethu M Madhavan; Martha Konieczkowski; Yaping Gu; Liping Luo; Zhenzhen Wu; Leslie A Bruggeman; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 10.121

9.  Cation channel conductance and pH gating of the innate immunity factor APOL1 are governed by pore-lining residues within the C-terminal domain.

Authors:  Charles Schaub; Joseph Verdi; Penny Lee; Nada Terra; Gina Limon; Jayne Raper; Russell Thomson
Journal:  J Biol Chem       Date:  2020-07-29       Impact factor: 5.157

10.  Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt
Journal:  Kidney Int       Date:  2018-02-03       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.